GSK Pharma reported strong Q3 performance with revenue up 18% and EBITDA rising 34%. Key brands, including Augmentin and ...
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback